Clinical Trial: Mirikizumab and Tirzepatide Concomitantly Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight: Phase 3b Study

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937099) titled 'Mirikizumab and Tirzepatide Concomitantly Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight: Phase 3b Study' on April 18.

Brief Summary: The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.

The maximum duration of this study is up to 61 weeks.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Crohn's Disease Obesity or Overweight

Intervention: DRUG: ...